ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Guideline
- Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.Journal for immunotherapy of cancer · 2018Guideline
- Phase 2 study of pembrolizumab in patients with advanced rare cancers.Journal for immunotherapy of cancer · 2020Trial
- An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).Journal for immunotherapy of cancer · 2019Trial
- FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation.Oncoimmunology · 2026Article
- Review
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.Molecular therapy. Oncology · 2026Article
- ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.JTO clinical and research reports · 2025Article
- Review
- New insights into the role of mast cells as a therapeutic target in cancer through the blockade of immune checkpoint inhibitors.Frontiers in medicine · 2024Review
- Anti-CTLA-4 treatment suppresses hepatocellular carcinoma growth through Th1-mediated cell cycle arrest and apoptosis.PloS one · 2024Article
- Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies.Cancers · 2023Review
- Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics.Life (Basel, Switzerland) · 2023Review
- Response-adaptive randomization in clinical trials: from myths to practical considerations.Statistical science : a review journal of the Institute of Mathematical Statistics · 2023Article
- Mast Cells and Resistance to Immunotherapy in Cancer.Archivum immunologiae et therapiae experimentalis · 2023Review
- Integrative analysis identified two subtypes and a taurine-related signature to predict the prognosis and efficacy of immunotherapy in hepatocellular carcinoma.Computational and structural biotechnology journal · 2023Article
- Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.The oncologist · 2022Article
- CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.Journal of cellular biochemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immunotherapy adds an exciting new dimension to the treatment of cancer, joining other approaches as a key pillar in the oncotherapeutics armamentarium. Immuno-oncology agents harbor unique mechanisms of antitumor activity by leveraging the host immune system, which may result in response patterns, resistance kinetics, and toxicity profiles that differ from other systemic therapies. These features have led to many discussions on ways to optimally integrate immunotherapy into cancer clinical trials. This overview provides an introduction to the four
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.